Suppr超能文献

英格兰大流行性流感 A/H1N1v 疫苗接种:实时经济评价。

Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation.

机构信息

Centre for Infections, Health Protection Agency, United Kingdom.

出版信息

Vaccine. 2010 Mar 11;28(12):2370-84. doi: 10.1016/j.vaccine.2010.01.002. Epub 2010 Jan 21.

Abstract

Decisions on how to mitigate an evolving pandemic are technically challenging. We present a real-time assessment of the effectiveness and cost-effectiveness of alternative influenza A/H1N1v vaccination strategies. A transmission dynamic model was fitted to the estimated number of cases in real-time, and used to generate plausible autumn scenarios under different vaccination options. The proportion of these cases by age and risk group leading to primary care consultations, National Pandemic Flu Service consultations, emergency attendances, hospitalisations, intensive care and death was then estimated using existing data from the pandemic. The real-time model suggests that the epidemic will peak in early November, with the peak height being similar in magnitude to the summer wave. Vaccination of the high-risk groups is estimated to prevent about 45 deaths (80% credibility interval 26-67), and save around 2900 QALYs (80% credibility interval 1600-4500). Such a programme is very likely to be cost-effective if the cost of vaccine purchase itself is treated as a sunk cost. Extending vaccination to low-risk individuals is expected to result in more modest gains in deaths and QALYs averted. Extending vaccination to school-age children would be the most cost-effective extension. The early availability of vaccines is crucial in determining the impact of such extensions. There have been a considerable number of cases of H1N1v in England, and so the benefits of vaccination to mitigate the ongoing autumn wave are limited. However, certain groups appear to be at significantly higher risk of complications and deaths, and so it appears both effective and cost-effective to vaccinate them. The United Kingdom was the first country to have a major epidemic in Europe. In countries where the epidemic is not so far advanced vaccination of children may be cost-effective. Similar, detailed, real-time modelling and economic studies could help to clarify the situation.

摘要

关于如何减轻不断演变的大流行的决策在技术上具有挑战性。我们实时评估了替代甲型 H1N1v 流感疫苗接种策略的有效性和成本效益。我们根据实时估计的病例数拟合了一个传播动力学模型,并使用该模型生成了在不同疫苗接种选择下的秋季情景假设。然后,根据大流行期间的现有数据,估计了这些病例中按年龄和风险组划分的导致初级保健咨询、国家大流行性流感服务咨询、紧急就诊、住院、重症监护和死亡的比例。实时模型表明,疫情将在 11 月初达到高峰,高峰高度与夏季波相似。为高风险人群接种疫苗估计可预防约 45 例死亡(80%置信区间 26-67),并节省约 2900 个 QALY(80%置信区间 1600-4500)。如果将疫苗购买本身的成本视为沉没成本,则此类方案很可能具有成本效益。将疫苗接种扩展到低风险人群预计将导致避免的死亡和 QALY 略有增加。将疫苗接种扩展到学龄儿童将是最具成本效益的扩展。早期获得疫苗对于确定此类扩展的影响至关重要。在英格兰已经有相当数量的 H1N1v 病例,因此疫苗接种减轻正在进行的秋季波的效果有限。然而,某些人群似乎面临更高的并发症和死亡风险,因此为他们接种疫苗似乎既有效又具有成本效益。英国是欧洲第一个发生重大疫情的国家。在疫情尚未如此严重的国家,为儿童接种疫苗可能具有成本效益。类似的、详细的、实时的建模和经济研究可以帮助澄清情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验